'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer

(MedPage Today) -- NEW YORK -- A post-hoc analysis of overall survival (OS) in the SOLO3 trial demonstrated why olaparib (Lynparza) recently had its fourth-line indication in ovarian cancer pulled by drugmaker AstraZeneca. The phase III trial...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news